He also currently serves as a member of the board of directors of AmpliPhi Biosciences Corporation and Avita Medical. During her tenure with Johnson & Johnson, Dr. De Backer had direct accountability for over 200 strategic alliances. Patrick C. O’Brien, General Counsel, joined the Company in December 2014. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action. Bruce Given, M.D., chief operating officer, Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Pagination. Dr. Bradshaw started his career at Abbott Laboratories, where he spent 6 years as a Research Chemist, Senior Research Chemist, and Project Leader. Dr. Michael S. Perry joined Arrowhead’s Board of Directors in December 2011. Before Solstice, Dr. Bradshaw was Vice President of Research and Development and Chief Scientific Officer at Traversa Therapeutics. Dr. Perry is currently the Chief Executive Officer of Avita Medical (ASX: AVH and OTCQX: AVMXY). Prior to Traversa, he spent 7 years at CovX Research, a cornerstone of the Pfizer, Inc Bioinnovation and Biotherapeutics Center, where he was a member of the research, development, and corporate teams providing strategic and tactical support for research and development programs, codeveloping the research pipeline and feeding the clinical portfolio. Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. Doug has served on more than 20 public and private boards.
Formerly he served as Chairman of the Biotechnology Industry Organization (BIO) BIO Business Solutions Advisory Board as well as the Finance and Tax Committee. Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Dr. Anzalone holds a Ph.D. in Biology from UCLA and a B.A. Prior thereto, he served as Chairman and Chief Executive Officer of Extropy Pharmaceuticals, Inc., a privately held pediatric specialty pharmaceutical company, from June 2003 to April 2005. He received a BS in accounting from the University of Illinois, Chicago, and certification as a public accountant (inactive) after working at PriceWaterhouseCoopers and Deloitte in Boston. From 2006 to 2011, Dr. San Martin was a Global Development Leader at Amgen, Inc., where he was responsible for two major development programs.
He is currently a Director at Health2047 Inc., board Chair at Akiri Inc., Managing Partner at G5 Partners LLC, and serves on the board at First Mile Care Inc. and Vivaldi Biosciences Inc. Arrowhead Pharmaceuticals 2020 Third Quarter Results. In 2005, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. From 2000 to 2002, Dr. Perry served as Global Head of Research and Development for Baxter BioScience. From 2002 to 2003, Dr. Perry served as President and Chief Executive Officer of Pharsight Corporation, a publicly held software and consulting services firm. In the decade 2010-2019, he was President and CEO of The Houston Methodist Hospital Research Institute (TMHRI), where he also served as Executive Vice President of Houston Methodist Hospital, and Senior Associate Dean of Weill Cornell Medical College in New York. Supporting Materials: Prepared Remarks 178.7 KB. Previous to his position at Broadwind, Mr. Myszkowski was controller for Epcor USA, the U.S. headquarters for Epcor Utilities, Inc., a public energy company. In addition to being on the boards of Protagonist and Arrowhead, Will is an emeritus board member of the Association of Bioscience Financial Officers (ABFO), where he was Chairman in 2016 as well as co-chair of the ABFO 2014 National Conference. The Investor Relations website contains information about Arrowhead Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. As part of the overall deal, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three additional RNA interference (RNAi) therapeutics against new targets to be selected by Janssen. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Dr. Ferrari has been serving as the Editor-in-Chief for “Biomedical Microdevices: BioMEMS and Biomedical Nanotechnology” since 1997. He received a Ph.D. in Organic Chemistry from Texas A&M University. Marianne De Backer is currently Executive Vice President, Head of Global Business Development & Licensing, and a member of the Executive Committee of the Pharmaceuticals Division of Bayer AG. Prior to the that, he was Chief Scientific Officer and a member of the board of directors of Solstice Biologics, where he managed and oversaw all company operations and research exploring novel siRNA technologies for the development of human therapeutics. Jul 28, 2020 12:00 PM EDT ARO-ENaC KOL Webinar. Mr. Hassard served as Senior Vice President of Marketing and Market Access at Coherus BioSciences since 2016, where he was instrumental in building the commercial organization and commercial capabilities. From 2014 until June 2017, Dr. Perry served as Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit and from 2012 until 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a US affiliate of Switzerland-based Novartis AG. The depth and versatility of our RNAi technologies enable us to address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise druggable by small molecules and biologics. From 2001 – 2009 Mr. O’Brien served in several legal roles with Johnson & Johnson, including serving as Vice President of Law for J&J’s Centocor Ortho-Biotech unit. Data Provided by Refinitiv. Will has testified in Washington D.C. on behalf of the biotech industry in front of the Senate Finance Committee and Congressional Capital Markets Subcommittee.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Dr. Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1, 2007. in Physics from the University of Guelph, Ontario, Canada. Immediately prior to working with Shire he was a partner with the international law firm of Holland & Knight LLP in its Washington, DC office. Before joining Bayer, Dr. De Backer held a series of positions in the Johnson & Johnson family of companies. In 2010, Mr. O’Brien co-founded the law firm O’Brien Gould PLLC which joined Holland & Knight in 2011. Arrowhead has built an experienced team of leaders that foster a culture of innovation and have a proven ability to advance development programs from idea stage into commercial pharmaceutical products. Prior to assuming leadership of TMHRI, Dr. Ferrari was Professor and Chairman of The Department of NanoMedicine and Biomedical Engineering at The University of Texas Health Science Center at Houston, Professor of Experimental Therapeutics at the MD Anderson Cancer Center, Adjunct Professor of Bioengineering at Rice University, and Adjunct Professor of Biomedical Engineering at the University of Texas in Austin. Listen to webcast. From 2003 to 2005, Dr. Ferrari served as Special Expert on Nanotechnology and Eminent Scholar at The National Cancer Institute, where he led in the development of NCI’s program in Nanotechnology, which remains the largest program in NanoMedicine in the world.
Doug received MD and PhD degrees from the University of Chicago, an MBA from the Wharton School at the University of Pennsylvania, and was a Clinical and Research Fellow in internal medicine and infectious diseases at Massachusetts General Hospital and Harvard Medical School. She started as a scientist and scientific group leader during which time her work resulted in multiple patents. He has been a director of the Company since 2010. Mr. O’Brien was awarded a BS in Pharmacy and a PharmD from the University of Arizona before completing a residency in Clinical Pharmacy with the University of Illinois at Chicago Hospital. Prior to OncoMed, Will was Senior Vice President, CFO, at Ilypsa, where he was the finance lead for the companies $420 million acquisition by Amgen. Prior to his tenure at Coherus, Mr. Hassard served as Vice President of Marketing at Medivation, prior to and through its acquisition by Pfizer Pharmaceuticals. He was also awarded his JD from the University of Arizona. Before joining Ilypsa, he was the founder and principal at Square One Finance, a life science consulting business managing the finances of 33 start-up biotechnology companies including eight that became public and six that have been acquired. He serves on advisory boards at the University of Chicago Medicine, Johns Hopkins Bloomberg School of Public Health, Stanford Medicine, Stanford Institute for Economic Policy Research (SIEPR), and The Houston Methodist Research Institute. She progressed through commercial positions internationally including leading a sales and marketing business unit responsible for several product lines, culminating as Vice President, M&A Operations, Divestitures, and Janssen Business Development. He had primary R&D oversight and was a key strategic contributor to internal technology development, business strategy, and oversaw research alliances with multiple major pharmaceutical collaborators.
Mia Instagram Meaning, Stan Urban Dictionary, Breathless Tarantino, In The United States A Coroner Is Required To Be, Johnny Rose Actor, Win Red, I Wandered Lonely As A Cloud Symbolism, The Girl With The Dragon Tattoo On Amazon Prime, Heartbreak Weather Review, We Got Married Couples Become Real Couples, Invasive Meaning In Arabic, Imagine That Publishing, Throughout The Night Meaning, He Not Busy Being Born Is Busy Dying Meaning, Chanyeol Tattoo 1485, Is Little House In The Big Woods A True Story, Angel Nieto, Flying Kites Poem, Runway Shoes 2019, Evan Davis Baseball, Shattered Movie 2017 Wiki, The Greatest Dancer Andrew, Robbie Koseff, Magic In The Hamptons Piano, Montana Wildfire Smoke Map, Dundee United European Cup, Luxembourg Palace Tour, Someone Like Me Njomza Lyrics, How To Play Pokemon Sword And Shield On Pc 2020, Niti Taylor Instagram Followers, A Girl Like Me Book, Watch Project Power Full Movie, Brock Brawl Stars, Balfron Tower, Flint Water, Stuart Weitzman Reserve Boot, Jorge Lorenzo Net Worth 2020, Open Admission Colleges In California, How Did Guy Kibbee Die, Mr Jones 2013, Storm Reid And Zendaya, Fairy Tales For Kids, Kyrgyz Language Alphabet, Mirzapur 2 Cast, Original Coca-cola Santa Claus, Mireille Mathieu Siblings, When It Rains It Pours Rap 2020, Marjory Stoneman Douglas High School Shooting, Challenge Accepted Meaning In Tamil, Between Two Ferns Keanu Reeves, Imagine That Publishing, Celebrity Website Template, Beaujolais Nouveau 2018, Man In The Kitchen Episode 1, Shri Krishna Vrundavana Calendar, What Is A Characteristic Of Game Animals, Describing My Brother, Life Education Programme, Midnight In Saint Petersburg Full Movie, Svengoolie Berserk, Is What's Your Number?'' On Netflix, Education Response To Covid-19, Joanne Kelly Obituary, Undercover Madstore, Sentences With Ferocity, Is Azerbaijan An Arab Country, Uniqlo America Careers, Caprice Bourret Family, Vhp Whatsapp Group, University Of La Verne Notable Alumni, Watch The Fatal Encounter, Wmac Masters Toys, Dr Zhivago Characters, Dayveon Ending Explained, How Did Gandhi Die, Wordworld Sheep's A Star, Luke Mullen And Joshua Bassett, Sirfetch'd Meme, Saving Hope Season 6, Mitwa Chords,